In This Article:
-
Total Revenue: $74.1 million, a 61% increase from the previous year.
-
IBSRELA Net Sales Revenue: $44.4 million, a 57% increase year-over-year.
-
XPHOZAH Net Sales Revenue: $23.4 million, a 55% increase year-over-year, excluding a one-time $3.8 million returns reserve release, the growth was 30%.
-
Gross Net Deduction for IBSRELA: 34.8% for the quarter.
-
Gross Net Deduction for XPHOZAH: Approximately 18%, excluding the returns reserve release, it was approximately 32%.
-
Research and Development Expenses: $14.9 million, up from $10.6 million the previous year.
-
Selling, General and Administrative Expenses: $83.2 million, compared to $53 million the previous year.
-
Net Loss: Approximately $41.1 million or $0.17 per share, compared to a net loss of $26.5 million or $0.11 per share the previous year.
-
Cash, Cash Equivalents, and Short-term Investments: $214 million as of March 31, 2025.
-
Milestone Payment: $5 million from Fosun Pharma for the approval of tenapanor in China.
Release Date: May 01, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Ardelyx Inc (NASDAQ:ARDX) reported a significant revenue growth of 61% year-over-year, reaching $74 million in the first quarter of 2025.
-
IBSRELA showed a 57% increase in net sales revenue compared to the previous year, indicating strong demand and market penetration.
-
XPHOZAH achieved a 30% revenue growth year-over-year, excluding one-time adjustments, demonstrating its importance in managing phosphorus levels for patients.
-
The company reaffirmed its 2025 guidance of $240 million to $250 million in net sales for IBSRELA, with a clear path to achieving over $1 billion in peak annual net sales.
-
Ardelyx Inc (NASDAQ:ARDX) maintained a strong cash position with $214 million in cash, cash equivalents, and short-term investments as of March 31, 2025, supporting its ongoing operations and strategic initiatives.
Negative Points
-
The loss of Medicare Part D coverage for phosphate-lowering therapies has caused significant disruption in the dialysis market, affecting XPHOZAH's market dynamics.
-
The company experienced a net loss of approximately $41.1 million in the first quarter, compared to a net loss of $26.5 million in the same period last year.
-
Research and development expenses increased to $14.9 million, reflecting higher engagement with scientific and medical communities.
-
Selling, general, and administrative expenses rose to $83.2 million, up from $53 million in the prior year, due to expanded commercial activities and corporate infrastructure growth.
-
Ardelyx Inc (NASDAQ:ARDX) has not yet provided formal revenue guidance for XPHOZAH due to the fluid market environment and ongoing access complexities.